{
    "organizations": [],
    "uuid": "5dde64344e7555c160ca9075be997cbb8eda4c6c",
    "author": "",
    "url": "https://www.reuters.com/article/brief-prometic-presents-new-pbi-4050-cli/brief-prometic-presents-new-pbi-4050-clinical-data-from-ongoing-alstrm-syndrome-phase-2-trial-idUSFWN1RP0GE",
    "ord_in_thread": 0,
    "title": "BRIEF-Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 12, 2018 / 10:39 AM / Updated 22 minutes ago BRIEF-Prometic Presents New PBI-4050 Clinical Data From Ongoing Alström Syndrome Phase 2 Trial Reuters Staff \nApril 12 (Reuters) - Prometic Life Sciences Inc: \n* PROMETIC PRESENTS NEW PBI-4050 CLINICAL DATA FROM ONGOING ALSTRöM SYNDROME PHASE 2 TRIAL \n* PBI-4050 DECREASED INSULIN RESISTANCE IN LIVER \n* FAT BIOPSIES FURTHER DEMONSTRATE PBI-4050 CLINICAL ACTIVITY \n* CLINICAL ACTIVITY AND TOLERABILITY OF PBI-4050 WERE SUSTAINED WITH PROLONGED TREATMENT Source text for Eikon: Further company coverage:",
    "published": "2018-04-12T13:38:00.000+03:00",
    "crawled": "2018-04-12T14:16:37.020+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "updated",
        "minute",
        "ago",
        "present",
        "new",
        "clinical",
        "data",
        "ongoing",
        "alström",
        "syndrome",
        "phase",
        "trial",
        "reuters",
        "staff",
        "april",
        "reuters",
        "prometic",
        "life",
        "science",
        "inc",
        "prometic",
        "present",
        "new",
        "clinical",
        "data",
        "ongoing",
        "alström",
        "syndrome",
        "phase",
        "trial",
        "decreased",
        "insulin",
        "resistance",
        "liver",
        "fat",
        "biopsy",
        "demonstrate",
        "clinical",
        "activity",
        "clinical",
        "activity",
        "tolerability",
        "sustained",
        "prolonged",
        "treatment",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}